Reading Time: 2 minutes

New York, New York–(Newsfile Corp. – May 6, 2021) – Enerkon Solar International (OTC Pink: ENKS) announces today the filling of Q2 March 31 Report today with the OTC Markets and positive Revenue and Growth and agrees to Appoint Famous Biotech Analyst Dr. Harvey Tran as Board Consultant and Adviser.

ENKS – 122 acres of commercial land to establish the planned 20 MW Solar and Hydrogen Plant facility

To view an enhanced version of this graphic, please visit:

Enks – 122 Acres of Commercial Land to Establish the Planned 20 Mw Solar and Hydrogen Plant Facility Part 2

To view an enhanced version of this graphic, please visit:

ENKS USA Based Utility Scale Solar Power and Hydrogen Production Project

To view an enhanced version of this graphic, please visit:

The foregoing statements are forward-looking statements, and as such, they may or may not reflect the results which could transpire in the future which should be negative or not transpire at all due to circumstances or other reasons and investors, shareholders, or others should not rely on these forward-looking statements to ascertain any value if any of ENKS or to make any investment decisions and to take note that this is not an offer to buy or sell securities or an endorsement of ENKS for investment purposes as all investment carry a risk of loss sometimes a total loss of your investment in Micro cap shares markets or any market and therefore such statements or plans should not be relied upon for any business decisions of any kind – Approval and permissions required by federal regulations may or may not be approved and if not approved may result in the loss of all value and all investments in products requiring such regulatory permissions to market and sell. These statements are made as forward-looking statements for educational purposes only in accordance with the rules and regulations which pertain to the same.

Enerkon Solar International Inc.
[email protected]

New HQ Address in New York at:
Enerkon Solar International Inc
477 Madison Avenue
New York, NY 10022 USA

Tel. +1 (877) 573-7797
Tel. +1 (718) 709-7889

To view the source version of this press release, please visit

Powered by WPeMatico